NPRL2基因与奥沙利铂治疗结直肠癌的研究进展  

Advances in Study on NPRL2 Gene and Oxaliplatin in Treatment of Colorectal Cancer

作　　者：付伟然 刘艾芸 杜雅菊[1] FU Weiran;LIU Aiyun;DU Yaju(Department of Gastroenterology, the 2 nd Affiliated Hospital of Harbin Medical University, Harbin (150001))

机构地区：[1]哈尔滨医科大学附属第二医院消化内科,150001

出　　处：《胃肠病学》2017年第12期760-763,共4页Chinese Journal of Gastroenterology

摘　　要：结直肠癌(CRC)是全球三大恶性肿瘤之一,具有高发病率和高死亡率。研究发现,NPRL2基因与CRC发生、发展关系密切,CRC患者NPRL2基因表达显著降低。奥沙利铂是第三代铂类抗肿瘤药物,已广泛应用于胃肠道肿瘤化疗,可提高CRC患者生存率,但部分患者存在耐药。NPRL2基因可增加奥沙利铂治疗CRC的敏感性,是CRC潜在的治疗靶点。本文就NPRL2基因与奥沙利铂治疗CRC的研究进展作一综述。Colorectal cancer(CRC)is one of the three major malignant tumors in the world with high morbidity and mortality.It is found that NPRL2gene is closely related to the occurrence and development of CRC,and the expression of NPRL2gene in CRC patients is significantly reduced.Oxaliplatin is the third generation of platinum anticancer drugs,and has been widely used in the chemotherapy of gastrointestinal tumors.Oxaliplatin can improve the survival rate of CRC patients,but some patients have drug resistance.NPRL2gene can increase the sensitivity of oxaliplatin in the treatment of CRC,and is a potential target for treatment of CRC.This article reviewed the advances in study on NPRL2gene and oxaliplatin in the treatment of CRC.

关 键 词：结直肠肿瘤 NPRL2基因 奥沙利铂 治疗 

分 类 号：R735.34[医药卫生—肿瘤]